Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
Official title: Project 1: Incorporating antibody drug conjugates into mechanism-based combinations to target metastatic breast cancer
Funded at Dana-Farber Cancer Inst · NIH-11414842 · Data updated 2026-11-12
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 17, 2013 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $413,263 |
| NIH project number | 5P50CA168504-12 |
| Project ID | NIH-11414842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic triple-negative breast cancer or related conditions who may be candidates for ADC-based therapies.
✕Less likely to help
Patients whose cancer does not respond to ADC-based combinations or cannot tolerate their toxicity may not benefit.
What this research studies
This project looks for smarter ways to use antibody-drug conjugates to attack metastatic triple-negative breast cancer (mTNBC) while decreasing side effects. Researchers will explore mechanism-based drug combinations, guided by biomarkers and CRISPR screens, to identify which partners boost efficacy. The work draws on past successes with ADCs like SG and aims to overcome resistance and improve patient outcomes. The plan includes clinical and translational components at Dana-Farber, building on prior trials to optimize dosing and sequencing. The ultimate goal is to offer more effective, safer options for people with mTNBC who currently have limited choices.
Why it matters
Potential benefit: If successful, patients with metastatic triple-negative breast cancer could receive more effective treatments with fewer side effects.
How similar studies have gone: Previous ADC strategies have yielded meaningful responses in some patients, and this project seeks to build on that success with new combinations.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Ellisen, Leif W — Dana-Farber Cancer Inst
- Study coordinator: Ellisen, Leif W
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Personalized therapies for metastatic breast cancer using patient-derived models
Doctors and researchers are testing how patient-derived tumor models can help find effective treatments for metastatic breast cancer and predict which therapies will work based on molecular clues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.